CSI Market
Sign In | Register

Amryt Pharma Plc (AMYT) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access AMYT Annual Cash Flow →
A period-by-period view of cash flow from Amryt Pharma Plc to Dec 31 2020 helps clarify how Dec 31 2021's cash position has changed over time.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Dec 31 2021)
12 Months 		0 0 0 (Dec 31 2020)
Operating Activities
Income-6.56
Depreciation & amortization0.00
Amortization of Other Assets4.42
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Adjustments For Decrease IncreaseIn Other Assets0.52
Share-based Compensation0.00
Income (Loss) from Equity Method Investments-4.14
Financial Instruments and Foreign Currency Transaction0.00
Adjustments For Finance Income Cost-
Adjustments For Depreciation And Amortisation Expense-
Gains Losses On Disposals Of Property Plant And Equipment-
Adjustments For Sharebased Payments-
Increase Decrease In Contingent Consideration Asset Liability-
Gain Loss On Remeasurement Of Reimbursement Rights-
Impairment Loss Recognised In Profit Or Loss Intangible Assets Other Than Goodwill-
Adjustments For Decrease Increase In Trade And Other Receivables-
Adjustments For Increase Decrease In Trade And Other Payables-
Adjustments For Provisions-
Adjustments For Decrease Increase In Inventories-
Income taxes-9.27
Purchase Of Intangible Assets Classified As Investing Activities0.82
Accounts Receivable0.00
Accounts Payable0.00
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets0.00
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.82
Discontinued operations0.00
Net Cash flow from Operating Activities15.54
Investing Activities
Capital Expenditures0.73
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Dividends Received Classified As Investing Activities0.01
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net107.13
Discontinued operations0.00
Net Cash Flow from Investing Activities106.40
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings116.63
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-3.03
Increase Decrease In Cash And Cash Equivalents-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-125.43
Effect of exchange rate on cash flow-2.28
Discontinued operations0.00
Free Cash Flow16.27
Total Cash Flow118.80
4 historic quarters locked

Sign in to unlock the full Amryt Pharma Plc cash flow history.

Sign In Create Free Account

About Amryt Pharma Plc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001140361-22-016877

Figures are derived from filed reports and may be restated. Historical data is subject to revision.